Skip to content
NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

Globus Medical Inc. GMED

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.9B
▲ 16.7% YoY
$537.9M
▲ 422.3% YoY
$588.8M
▲ 45.3% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Globus Medical, Inc. offers a portfolio of technologies used to treat a variety of musculoskeletal conditions. Globus Medical, Inc. is headquartered in Audubon, Pennsylvania. As of December 31, 2025, it had over 6,000 employees worldwide, working in sales and marketing, product development, operations, and general administrative and accounting functions domestically and internationally. For the year ended December 31, 2025, international sales accounted for approximately 19.4% of its total sales. It manages its business globally within one reportable segment but separates its products and services into two categories, Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, surgical instruments, spinal cord stimulation treatment therapy, and neuromonitoring services used in spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies consist of imaging, navigation and robotics solutions used in assisted surgery. Globus was founded in 2003.

Written from the business description in GLOBUS MEDICAL, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.

Growth

USD 2.9B
Revenue, FY2025 · full 16-year series below
Revenue $B Net income $B
FY2025 · Revenue 2.9 · Net income 0.5
2B3B
201020132016201920222025
Compound annual growth
+42.2%
+30.1%
+18.4%
+16.7%
+41.4%
+39.4%
+16.9%
+16.5%
+28.4%
+31.2%
+12.9%
+13.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +30.1% a year over the five years to FY2025 — but profit grew faster: net income at +39.4%, earnings per share at +31.2%.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

18 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 16.3% · Net 18.3%
10%20%30%
201020172025
ROE
FY2025 · ROE 12.3%
10%20%
201020172025
Three returns, three denominators.

Each USD of equity produced 12 cents of profit this year.

Cash & shareholders

USD 210.7M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 588.8
250.0M500.0M
201020172025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 210.7
100M200M-10M-20M
201020112012201320202022202320242025

USD 210.7M in buybacks — 39% of the year's profit went back to shareholders.

Total assetsUSD 5.3B
EquityUSD 4.6B
CashUSD 526.2M
Current ratio4.26×

Equity funds 86% of total assets.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
GMED, 16-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B2.92.51.61.01.00.80.80.70.60.60.50.50.40.40.30.3
Operating income $B0.50.20.10.20.20.10.20.20.20.20.20.10.10.10.10.1
EBITDA $B0.80.40.30.30.20.20.20.20.20.20.20.20.10.10.10.1
Income tax $B0.10.00.00.10.00.00.00.00.10.10.10.00.00.00.00.0
Net income $B0.50.10.10.20.10.10.20.20.10.10.10.10.10.10.10.1
Free cash flow $B0.60.40.20.10.20.10.10.10.10.10.10.10.10.10.10.1
EPS, diluted $3.920.751.071.851.441.011.521.541.101.081.170.970.730.800.670.60
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————————
ROE %12.32.54.210.69.27.012.014.511.913.517.317.516.022.123.823.9
Shares out B◌◌◌◌◌◌0.100.100.100.100.100.090.090.090.07◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 76 reconciliationsAUDITED

Reconciled in 16 of the 16 fiscal years we could check. Eight checks were skipped: the balance sheet is not tagged before 2011. Three checks were skipped: EPS is not tagged before 2010. Three checks were skipped: revenue is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2010

Share this section

Download image